- Case Report
Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series
- Livija Šimičević,
- Ana Marija Slišković,
- Majda Vrkić Kirhmajer,
- Lana Ganoci,
- Hrvoje Holik,
- Jozefina Palić,
- Jure Samardžić and
- Tamara Božina
Non-vitamin K antagonist oral anticoagulants’ interindividual trough concentration variability affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via CYP3A4/5-, CYP2J2-, and CYP-independent mechanisms and is...

